摘要
目的:探讨分析对慢性心力衰竭的患者采用卡维地洛联合缬沙坦治疗的临床效果及安全性。方法:选取在我院诊治的慢性心力衰竭患者118例,根据数字随机法分成观察组和对照组,对照组采取缬沙坦治疗,观察组在此基础上,采取卡维地洛治疗,比较两组临床效果及安全性。结果:观察组左室收缩末内径、左室舒张末内径、左室收缩末容量、左室舒张末容量、左心室射血分数和心搏出量改善情况好于对照组,差异有统计学意义(P<0.05)。观察组总有效率为94.92%,对照组总有效率为83.05%,观察组总有效率比对照组高,差异有统计学意义(P<0.05)。两组均未处于严重的药物不良反应。结论:卡维地洛联合缬沙坦治疗为一种安全可靠的临床治疗慢性心力衰竭的方法。
Objective： To explore clinical effects and security analysis of combination of carvedilol and valsartan on patients with chronic heart failure. Methods： 118 patients with chronic heart failure patients in our hospital were divided randomly into observation group and control group according to the figure.The control group were taken vaIsartan and the observation group were taken carvedtlol treatment on the basis of taking valsartan in which the clinical effect and security were compared in two groups. Results： The left ventricular end -systolic diameter, left ventricular end -diastolic diameter, left ventncular end -systolic capacity, left ventricular end - diastolic volume, left ventricular ejection fraction and stroke volume were better improved in the observation group than that in the control group in which the difference was statistically significant （P〈0.05）. The total efficiency in observation group was 94.92%, the control group was 83.05% in which the difference was statistically significant （P〈0.05）. There was no serious adverse drug reactions in the observation group and control group. Conclusion：Combination of carvedilol and valsartan on patients with chronic heart failure is a safe and reliable treatment.
出处
《甘肃医药》
2014年第2期86-87,共2页
Gansu Medical Journal
